Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma
Daratumumab (Dara)-containing treatments have shown promising outcomes for relapsed and refractory multiple myeloma (RRMM) [1, 2]. Dara is an antibody against CD38, which is expressed not only on myeloma cells and B cells but also on natural killer cells and activated T cells . Although the necessity of prophylaxis for herpes zoster was described in previous studies of daratumumab and recent guidelines from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Infections in Compromised Hosts, cytomegalovirus (CMV) reactivation was not mentioned . Recently, a few cases of CMV reactivation after Dara treatment have been reported in patients with RRMM [5, 6].
Compliance with ethical standards
This case study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Investigators C (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766. https://doi.org/10.1056/NEJMoa1606038 CrossRefGoogle Scholar
- 2.Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O’Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331. https://doi.org/10.1056/NEJMoa1607751 CrossRefGoogle Scholar
- 4.Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M (2018) ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 24(Suppl 2):S83–S94. https://doi.org/10.1016/j.cmi.2018.03.022 CrossRefGoogle Scholar
- 8.Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384–394. https://doi.org/10.1182/blood-2015-12-687749 CrossRefGoogle Scholar